PDCD1 and neoplasm: Homozygous mutation of JAK1/2 was detected in post-treatment samples collected from melanoma patients who had tumor progression after initial response, suggesting clonal selection and proliferation of JAK-inactive tumor cells after applying the PD1 blockade (Zaretsky et al., 2016).